Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The expression of teneurin-4 in the avian embryo.
Tucker RP, Martin D, Kos R, Chiquet-Ehrismann R. Tucker RP, et al. Among authors: kos r. Mech Dev. 2000 Nov;98(1-2):187-91. doi: 10.1016/s0925-4773(00)00444-5. Mech Dev. 2000. PMID: 11044628 Free article.
Dried Blood Spot Method Development and Clinical Validation for the Analysis of Elexacaftor, Elexacaftor-M23, Tezacaftor, Tezacaftor-M1, Ivacaftor, Ivacaftor Carboxylate, and Hydroxymethyl Ivacaftor Using LC-MS/MS.
Vonk SEM, van der Meer-Vos M, Kos R, Neerincx AH, Terheggen-Lagro SWJ, Altenburg J, Maitland-van der Zee AH, Mathôt RAA, Kemper EM; Amsterdam Mucociliary Clearance Disease (AMCD) research group. Vonk SEM, et al. Among authors: kos r. Ther Drug Monit. 2024 Aug 27;46(6):804-12. doi: 10.1097/FTD.0000000000001231. Online ahead of print. Ther Drug Monit. 2024. PMID: 38935410 Free PMC article.
A BEAT-PCD consensus statement: a core outcome set for pulmonary disease interventions in primary ciliary dyskinesia.
Kos R, Goutaki M, Kobbernagel HE, Rubbo B, Shoemark A, Aliberti S, Altenburg J, Anagnostopoulou P, Athanazio RA, Beydon N, Dell SD, Emiralioglu N, Ferkol TW, Loebinger MR, Lorent N, Maître B, Marthin J, Morgan LC, Nielsen KG, Ringshausen FC, Shteinberg M, Tiddens HAWM, Maitland-Van der Zee AH, Chalmers JD, Lucas JSA, Haarman EG. Kos R, et al. ERJ Open Res. 2024 Jan 8;10(1):00115-2023. doi: 10.1183/23120541.00115-2023. eCollection 2024 Jan. ERJ Open Res. 2024. PMID: 38196895 Free PMC article.
Precision Medicine for More Oxygen (P4O2)-Study Design and First Results of the Long COVID-19 Extension.
Baalbaki N, Blankestijn JM, Abdel-Aziz MI, de Backer J, Bazdar S, Beekers I, Beijers RJHCG, van den Bergh JP, Bloemsma LD, Bogaard HJ, van Bragt JJMH, van den Brink V, Charbonnier JP, Cornelissen MEB, Dagelet Y, Davies EH, van der Does AM, Downward GS, van Drunen CM, Gach D, Geelhoed JJM, Glastra J, Golebski K, Heijink IH, Holtjer JCS, Holverda S, Houweling L, Jacobs JJL, Jonker R, Kos R, Langen RCJ, van der Lee I, Leliveld A, Mohamed Hoesein FAA, Neerincx AH, Noij L, Olsson J, van de Pol M, Pouwels SD, Rolink E, Rutgers M, Șahin H, Schaminee D, Schols AMWJ, Schuurman L, Slingers G, Smeenk O, Sondermeijer B, Skipp PJ, Tamarit M, Verkouter I, Vermeulen R, de Vries R, Weersink EJM, van de Werken M, de Wit-van Wijck Y, Young S, Nossent EJ, Maitland-van der Zee AH; P4O2 consortium. Baalbaki N, et al. Among authors: kos r. J Pers Med. 2023 Jun 28;13(7):1060. doi: 10.3390/jpm13071060. J Pers Med. 2023. PMID: 37511673 Free PMC article.
Real-life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients.
Kos R, Neerincx AH, Fenn DW, Brinkman P, Lub R, Vonk SEM, Roukema J, Reijers MH, Terheggen-Lagro SWJ, Altenburg J, Majoor CJ, Bos LD, Haarman EG, Maitland-van der Zee AH; Amsterdam Mucociliary Clearance Disease (AMCD) Research Group. Kos R, et al. Pharmacol Res Perspect. 2022 Dec;10(6):e01015. doi: 10.1002/prp2.1015. Pharmacol Res Perspect. 2022. PMID: 36440690 Free PMC article.
73 results